Warner Chilcott announced the launch of a 200mg dosage strength for Doryx (doxycycline hyclate) delayed-release tablets. Doryx is a tetracycline antibiotic indicated as adjunct treatment in severe ...
On September 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co. (Doryx), the Third Circuit affirmed the lower court's grant of summary judgment against antitrust claims by ...
Lupin has received the Food and Drug Administration’s green light for Doxycycline Hyclate Delayed-Release tablets, 50 mg, 60 mg, 75 mg, 80 mg, 100 mg, 120 mg, 150 mg and 200 mg, which is the generic ...
On September 28, 2016, the Third Circuit issued an opinion in Mylan v. Warner Chilcott, upholding the Eastern District of Pennsylvania’s holding on summary judgement that Defendants’ “product hopping” ...
DUBLIN, Feb. 9, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx® brand ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New ...
We are positive on the approval of Doryx (200 mg) as it has extended the life cycle of the drug at Warner Chilcott, following the genericization of the 150 mg dosage of Doryx last year. We note that ...
Doxycycline (as hyclate) 60mg; del-rel tabs; contains sodium. Swallow whole. Take with fluids; may give with food or milk if gastric irritation occurs. 120mg every 12hrs for 1 day, then 120mg daily ...
Ten years ago, consumers were on the verge of getting a lower-priced, generic version of the brand name antibiotic Doryx (doxycycline). But the drug's manufacturer, Warner Chilcott, stopped making the ...
DUBLIN, Ireland, Sept. 22, 2011 (GLOBE NEWSWIRE) -- Warner Chilcott plc (Nasdaq:WCRX) today announced that the U.S. District Court for the District of New Jersey granted its motion for a preliminary ...
Actavis plc (ACT) entered into an agreement with Mayne Pharma for the divestment of U.S. rights to Doryx (acne) and related assets. Actavis will receive $50 million on completion of the deal. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results